0822 GMT - China's healthcare sector will likely get a significant boost from national policies in 1Q, Citi analysts write in a note. This year marks the start of the most positive structural change in the industry, as it will be the first time that China's public healthcare system is able to include commercial insurance providers as significant payers, they say. The brokerage recommends buying shares in companies that will be direct beneficiaries of the reform. These include pharmaceutical and biopharmaceutical firms, pharmaceutical distributors and medical device companies. Citi's top picks include Jiangsu Hengrui Medicine, Hansoh Pharmaceutical, SSY Group, Akeso, Sichuan Kelun-Biotech Biopharmaceutical, Mindray Medical, Sinopharm Group, WuXi AppTec, Wuxi Biologics and Gushengtang. (jiahui.huang@wsj.com; @ivy_jiahuihuang)
(END) Dow Jones Newswires
January 07, 2025 03:23 ET (08:23 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。